11 completed, 6 unknown, 4 recruiting, 2 withdrawn. 12 Phase 2, 8 Phase 1, 4 Not applicable, 1 Early Phase 1.
Follow Graft-versus-host-disease: new trials by email Literature Review of Graft-versus-host-disease trials Research Report on Graft-versus-host-disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome Busulfan, Melphalan, Fludarabine - Myelodysplastic Syndromes, Graft Vs Host Disease | Not applicable | Not yet recruiting | Guenther Koehne | 62 | 2027-01-01 | 2026-10-13 |
| TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant CliniMACS® device - Graft Vs Host Disease, Graft-versus-host-disease | Not applicable | Withdrawn | Neena Kapoor, M.D. | 2025-05-27 | 2025-07-14 | |
| Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia Mesenchymal Stromal Cells (MSC) Dose Level 0, Mesenchymal Stromal Cells (MSC) Dose Level 1 - Xerostomia, Graft-versus-host-disease | Phase 1 | Recruiting | University of Wisconsin, Madison | 36 | 2024-10-04 | 2026-08-19 |
| Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Ruxolitinib, Abatacept - Graft Vs Host Disease, Graft-versus-host-disease | Phase 1 | Recruiting | Washington University School of Medicine | 41 | 2024-05-07 | 2026-04-22 |
| SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography OCT (Optical Coherence Tomography) - Oral Squamous Cell Carcinoma, Oral Potentially Malignant Disorder | Recruiting | University of Palermo | 200 | 2024-03-13 | 2025-05-23 | |
| Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD Physical therapy - Graft-versus-host-disease, Graft Versus Host Disease, Chronic | Not applicable | Unknown | University of Seville | 108 | 2024-03-01 | 2024-02-28 |
| Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease Letermovir - Graft-versus-host-disease, CMV | Phase 2 | Unknown | Rabin Medical Center | 42 | 2023-10-01 | 2023-08-01 |
| The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease Lifitegrast 5% Ophthalmic Solution, Placebo - Graft-versus-host-disease, Ocular Graft-versus-host Disease | Early Phase 1 | Completed | Richard W Yee, MD | 30 | 2022-10-22 | 2024-07-15 |
| A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. Cytarabine, Busulfan, Cyclophosphamide - Leukemia, Graft-versus-host-disease | Phase 2 | Unknown | Yi Luo | 46 | 2020-12-03 | 2023-02-21 |
| PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT Ruxolitinib, Tacrolimus, Mycophenolate Mofetil - Graft-versus-host-disease, Stem Cell Transplant Complications | Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 128 | 2020-11-03 | 2025-07-04 |
| HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis Treatment Arm - high dose ATG, Control Arm - standard of care - Graft-versus-host-disease, Relapse | Phase 2 | Terminated | AHS Cancer Control Alberta | 68 | 2020-07-01 | 2025-07-18 |
| Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation Baricitinib - Graft-versus-host-disease, Graft Vs Host Disease | Phase 1 | Completed | Washington University School of Medicine | 26 | 2020-04-07 | 2023-05-10 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine) - Hematologic Diseases, Acute Leukemia in Remission | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 43 | 2020-02-04 | 2026-01-27 |
| A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant CliniMacs® - Graft Vs Host Disease, Graft-versus-host-disease | Not applicable | Recruiting | Christopher Dvorak | 90 | 2019-12-19 | 2026-04-13 |
| RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation RGI-2001, Standard of Care - Graft Vs Host Disease, Graft-versus-host-disease | Phase 2 | Completed | Regimmune Corporation | 49 | 2019-11-25 | 2024-05-28 |
| Prevalence of Chronic Oral Graft Versus Host Disease Risk Factors in Pediatric Patients Oral Disease, Graft-versus-host-disease | Unknown | yasmeen magdi sholkamy | 250 | 2019-04-01 | 2019-03-20 | |
| Itacitinib for Low Risk GVHD Itacitinib - Low Risk Acute Graft-versus-host Disease, Graft-versus-host-disease | Phase 2 | Completed | John Levine | 70 | 2019-03-25 | 2023-02-06 |
| CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease BMS-986004, Sirolimus, Tacrolimus - Graft-versus-host-disease, GVHD | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 45 | 2019-02-15 | 2026-04-02 |
| A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD Alpha 1-Antitrypsin - Graft-versus-host-disease, GVHD | Phase 2 | Completed | John Levine | 30 | 2018-08-17 | 2021-07-12 |
| Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation Belimumab - Graft Vs Host Disease, Graft-versus-host-disease | Phase 1 | Completed | Washington University School of Medicine | 10 | 2018-05-16 | 2026-04-20 |
Showing 20 of 27. Sign in to see all of them.
Graft vs Host Disease (27) · Leukemia, Myeloid, Acute (3) · Hematologic Neoplasms (2) · Mouth Diseases (2) · Myelodysplastic Syndromes (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Actinic cheilitis (1) · Blast Crisis (1) · Bronchiolitis Obliterans Syndrome (1) · Dry Eye Syndromes (1) · Hematologic Diseases (1) · Keratosis, Actinic (1) · Leukemia (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Chronic-Phase (1)
Immune System Diseases (27) · Hemic and Lymphatic Diseases (7) · Neoplasms (7) · Hematologic Diseases (6) · Neoplasms by Histologic Type (6) · Leukemia (4) · Leukemia, Myeloid (4) · Pathological Conditions, Signs and Symptoms (4) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms by Site (3) · Pathologic Processes (3) · Stomatognathic Diseases (3) · Bone Marrow Diseases (2)
Tacrolimus (4) · Mycophenolic Acid (3) · Busulfan (2) · Cyclophosphamide (2) · Cyclosporine (2) · Sirolimus (2) · Standard of Care (2) · alpha 1-Antitrypsin (2) · ruxolitinib (2) · Abatacept (1) · Blood Specimen Collection (1) · Cytarabine (1) · Interleukin-2 (1) · KRN 7000 (1) · Melphalan (1)
Washington University School of Medicine (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · John Levine (2) · AHS Cancer Control Alberta (1) · Cambium Bio Limited (1) · Christopher Dvorak (1) · Guenther Koehne (1) · Impatients N.V. trading as myTomorrows (1) · N.M. Wulffraat (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Neena Kapoor, M.D. (1) · Rabin Medical Center (1) · Regimmune Corporation (1) · Richard W Yee, MD (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1)
United States (14) · China (2) · Canada (1) · Germany (1) · Italy (1) · Netherlands (1) · Russia (1) · Spain (1)
Brian Betts, MD (1) · Christopher C Dvorak, MD (1) · Edmund K Waller, MD PhD (1) · Farhad Khimani, M.D. (1) · Guenther Koehne, M.D., Ph.D. (1) · Iskra Pusic, M.D. (1) · Jacques Galipeau, MD (1) · Jan Storek, MD (1) · John Levine, MD (1) · John Levine, MD, MS (1) · Jurgen H Kuball, MD (1) · Maria Vehreschild, MD (1) · Mark A Schroeder, M.D. (1) · Moshe Yeshurun, MD (1)
PMID 28104702, PMID 33351103, PMID 36095841, PMID 39042892, PMID 40680268, PMID 42066960, PMID 42784255
P01CA039542 (1), UL1TR002240 (1)